|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500112460 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-14 09:44:00 |
|
注册时间: Date of Registration: |
2025-11-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
替妥尤单抗治疗甲状腺相关眼病的临床效:多中心前瞻性真实世界研究 |
|
Public title: |
Clinical Efficacy of Teprotumumab in the Treatment of Thyroid-Associated Ophthalmopathy: A Multicenter Prospective Real-World Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
替妥尤单抗治疗甲状腺眼病的临床疗效: 多中心前瞻性观察性登记性研究 |
|
Scientific title: |
Clinical Efficacy of Teprotumumab in the Treatment of Thyroid Eye Disease: A Multicenter Prospective Observational Registry Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
甘路 |
研究负责人: |
钱江 |
|
Applicant: |
Lu Gan |
Study leader: |
Jiang Qian |
|
申请注册联系人电话: Applicant telephone: |
+86 188 0173 5716 |
研究负责人电话:
Study leader's |
+86 21 6437 7134 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
ganlu1808@126.com |
研究负责人电子邮件: Study leader's E-mail: |
qianjiang@fudan.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区汾阳路83号 |
研究负责人通讯地址: |
上海市徐汇区汾阳路83号 |
|
Applicant address: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
Study leader's address: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属眼耳鼻喉科医院 |
||
|
Applicant's institution: |
Eye and ENT hospital of Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属眼耳鼻喉科医院 |
||
|
Affiliation of the Leader: |
Eye and ENT hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025]伦审字第(2025135)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属眼耳鼻喉科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Eye and ENT hospital of Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-06-20 00:00:00 | ||
|
伦理委员会联系人: |
吴仪菡 |
||
|
Contact Name of the ethic committee: |
Yihan Wu |
||
|
伦理委员会联系地址: |
上海市徐汇区汾阳路83号 |
||
|
Contact Address of the ethic committee: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6437 7134 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
复旦大学附属眼耳鼻喉科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Eye and ENT hospital of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区汾阳路83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 83, Fenyang Road, Xuhui District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国研究型医院学会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chinese Research Hospital Association |
||||||||||||||||||||||
|
研究疾病: |
甲状腺眼病 |
||||||||||||||||||||||
|
Target disease: |
Thyroid Eye Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
评估替妥尤单抗对甲状腺眼病(Thyroid eye disease, TED)受试者的综合疗效;评估静脉滴注替妥尤单抗的安全性和耐受性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the comprehensive efficacy of Teprotumumab in subjects with Thyroid Eye Disease (TED); to assess the safety and tolerability of intravenous infusion of Teprotumumab. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.已满18周岁; 2.符合《中国甲状腺相关眼病诊断和治疗指南(2022年)》TED诊断标准; 3.研究者与受试者沟通后已决定使用替妥尤单抗; 4.充分知情同意。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged 18 years or older. 2. Meets the diagnostic criteria for TED as defined by the Chinese guideline on the diagnosis and treatment of thyroid? associated ophthalmopathy (2022). 3. The decision to use Teprotumumab has been made by the investigator following communication with the subject. 4. Has provided written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.处于妊娠/哺乳期或近半年计划妊娠(不限性别); 2.基线听力受损:任一耳存在耳鸣或其他听力受损病史; 3.糖尿病血糖控制不佳:糖化血红蛋白≥ 9.0%; 4.近6个月内使用过利妥昔单抗; 5.近2个月内使用过托珠单抗; 6.对替妥尤单抗或药品成分中任何一种辅料过敏; 7.研究者评估认为有不适合参加本研究理由者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnancy, lactation, or planning to become pregnant within the next six months (applicable to subjects of either sex). 2. Baseline hearing impairment: A history of tinnitus or other hearing impairment in either ear. 3. Poorly controlled diabetes mellitus: Glycated hemoglobin (HbA1c) ≥ 9.0%. 4. Previous use of Rituximab within the past 6 months. 5. Previous use of Tocilizumab within the past 2 months. 6. Known hypersensitivity to Teprotumumab or any excipient in the formulation. 7. Any other reason deemed by the investigator to make the subject unsuitable for participation in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-10-20 00:00:00至 To 2027-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-14 00:00:00 至 To 2026-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子病例记录表(eCRF)和电子采集和管理系统(EDC) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Case Record Form(eCRF) and Electronic Data Capture (EDC) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |